Author:
Ehlers Lars H.,Lamotte Mark,Ramos Mafalda C.,Sandgaard Susanne,Holmgaard Pia,Kristensen Malene M.,Ejskjaer Niels
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference48 articles.
1. Ramos M, Men P, Wang X, Ustyugova A, Lamotte M. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Eff Resour Alloc. 2021;19(1):46.
2. Sundhedsstyrelsen. Farmakologisk glukosesænkende behandling af type 2-diabetes i almen praksis, Rationel Farmakoterapi nr. 2020. https://www.sst.dk/da/Udgivelser/2020/Rationel-Farmakoterapi-10-2020. Accessed 10 Sep 2020.
3. Statens Institut for Folkesundhed. Sygdomsudviklingen i Danmark fremskrevet til 2030. 2020. https://www.sdu.dk/sif/-/media/images/sif/sidste_chance/sif/udgivelser/2017/sygdomsudviklingen_i_danmark_fremskrevet_til_2030.pdf.
4. Carstensen B, Rønn PF, Jørgensen ME. Components of diabetes prevalence in Denmark 1996–2016 and future trends until 2030. BMJ Open Diabetes Res Care. 2020;8:1.
5. Ehlers LH, Lamotte M, Monteiro S, et al. The cost-effectiveness of empagliflozin versus liraglutide treatment in people with type 2 diabetes and established cardiovascular disease. Diabetes Ther. 2021;12(5):1523–34.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献